Irccs Synlab Sdn
Naples, 80146, Italy
NCT Number: NCT06877182
Identifying, screening and monitoring individuals at risk of Alzheimer's disease (AD) and dementia is a formidable challenge. Neuroimaging, and in particular magnetic resonance imaging (MRI), is crucial to detect structural neurodegeneration. However, current quantification tools are mainly limited to research contexts and produce non-standardised results. DIADEMA will build a systematic and standardised workflow to support neuro(radio)logical diagnosis. By combining artificial intelligence (AI) and machine learning (ML) the investigators will significantly enhance the clinical diagnosis of AD in neuroradiology. The investigator's main hypothesis is that an efficient workflow and associated higher diagnostic accuracy will substantially reduce healthcare costs, support clinical decision-making, provide second-opinion tools and improve patient care. This dual advance will have a profound impact on the healthcare system, marking an important step in the fight against Alzheimer's disease and dementia.
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Observational
Naples, 80146, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
To evaluate the possibility to improve the neuroradiologic workflow with AI models
Time frame: 1-36 month
ROC curves
IRCCS SYNLAB SDN
Other
Acronym: DIADEMA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05508789
Alzheimer Disease, Brain Diseases
ABB, Argentina
View Trial DetailsNCT04692441
Alzheimer Disease, Brain Diseases
Seattle, Washington, United States
View Trial DetailsNCT05607732
Alzheimer Disease, Brain Diseases
Chicago, Illinois, United States
View Trial DetailsNCT05596760
Alzheimer Disease, Arterial Occlusive Diseases
Seattle, Washington, United States
View Trial Details